Further, observations from the current study show that the combination of plasma GFAP and plasma Aβ1–42/Aβ1–40 ratios along with the major AD risk factors, have the potential to differentiate between Aβ+ and Aβ− individuals, albeit further studies in independent cohorts are required to validate these findings. Here, GFAP is linked to Alzheimer disease.